Accelerate Program for Quebec Emerging Companies
QC, Canada
Support for Therapeutics, Med-Tech and Digital Health innovators
grant_single_labels|summary
grant_single|eligibleFinancing
- grant_single|noCondition
grant_single|deadlines
- grant_single|openingDateAugust 20, 2021
grant_single|financingType
Grant and Funding
Expert Advice
grant_single|eligibleIndustries
- Manufacturing
- Professional, scientific and technical services
- Health care and social assistance
grant_single|grantors
- adMare Bioinnovations
grant_single|status
grant_card_status|open
grant_single_labels|preview
Get customized support and discounted rate on rental fees for lab and office spaces to help you advance to significant seed or Series A financing, if you’re an early-stage life sciences business.
grant_single_labels|projects
This grant is available to companies located in Canada, aligning with adMare's focus on Canadian life sciences companies. adMare supports companies across various Canadian cities with their innovation centres and offices.
- Companies located in Vancouver, British Columbia.
- Organizations operating in Toronto, Ontario.
- Businesses based in Montreal, Quebec.
grant_single|admissibleProjectsExample
$750,000
Developing early-stage diagnostics technology for infectious diseases
$800,000
Development of a novel gene therapy for rare genetic disorders
$600,000
Collaborative research with University of Ottawa on cancer biomarker discovery
$1,200,000
Translation of academic research to therapeutic products for Alzheimer's disease
$1,000,000
Initial development of a biodegradable nano-coating for medical implants
$1,100,000
Collaborative effort with Canadian researchers on revolutionary diabetes treatment
grant_single_labels|admissibility
Eligibility for this grant is determined by specific requirements related to the applicant's profile and proposed activities.
- The company must be part of the Canadian life sciences sector, focusing on biopharmaceuticals, medical devices, or digital health solutions.
- The technology proposed must demonstrate differentiation and a competitive advantage.
- The market opportunity for the technology must be significant.
- The company must have a high-quality team in place.
- The scope and strength of IP coverage must be clear and defendable.
- The proposed project must offer a potential return on investment.
- The seed investment must be capable of bringing the company to a value inflection point attractive to private capital.
grant_eligibility_criteria|who_can_apply
Academic researchers and emerging Canadian life sciences companies focused on biopharmaceuticals, medical devices, and digital health solutions can apply for this grant. AdMare seeks projects involving novel and transformative pre-clinical technologies with commercial potential that address unmet medical needs.
grant_eligibility_criteria|eligible_expenses
adMare provides opportunities for collaborations that transform academic research into new therapeutic products and bio-innovation companies. The eligible projects focus on early-stage technology development and company-building in the life sciences sector.
- Collaboration with researchers to translate leading academic research into therapeutics and health innovations.
- Identification and advancement of pre-clinical technologies addressing unmet medical needs.
- Creation of new Canadian life sciences companies by partnering with scientists and entrepreneurs.
- Development of a business case to attract private sector investment.
- Support for growth of existing life sciences companies through shared expertise and investment capital.
grant_eligibility_criteria|zone
The eligible geographic zones for this grant are locations within Canada, specifically including Vancouver, Toronto, and Montreal.
- Vancouver, British Columbia
- Toronto, Ontario
- Montreal, Quebec
grant_single_labels|criteria
The evaluation and selection criteria for projects under this grant focus on ensuring alignment with adMare's strategic investment goals.
- Differentiation and competitive advantage of the technology.
- Market opportunity and potential for growth.
- Quality and experience of the team involved.
- Scope and strength of intellectual property coverage.
- Potential return on investment.
- The impact of an adMare seed investment in building the company to a value inflection point that attracts private capital.
grant_single_labels|register
- Step 1: Identify opportunities
- Implications: Assess potential therapeutic opportunities discovered by Canadian researchers that have commercial potential.
- Step 2: Develop & advance technologies
- Implications: Collaborate with founding researchers to progress the discovery towards the next development milestone and investment readiness. Dedicate professional R&D resources and infrastructure to generate valuable data and IP.
- Step 3: Build partnerships
- Implications: Engage partners from academia, industry, patient foundations, the investment community, and key opinion leaders to support the advancement of technologies and creation of new companies.
- Step 4: Assemble a team
- Implications: Work with co-founders to build an experienced management and scientific team to create a compelling business case for investors.
- Step 5: Secure seed investment
- Implications: Evaluate the differentiation, market opportunity, team quality, IP coverage, and potential ROI to secure adMare seed investment that will make the company attractive to private capital.
grant_single_labels|otherInfo
grant_single_labels|contact
514.375.3334
Apply to this program
adMare's Grant: Empowering Canadian Life Sciences Innovation
This grant provides essential support to Canadian researchers and emerging life sciences companies by offering capital, expertise, and infrastructure. adMare aims to transform leading research into viable companies that contribute significantly to Canada's biopharmaceutical, medical device, and digital health sectors.
Unleashing Potential Through adMare's Strategic Investments
adMare's grant is a pivotal initiative aimed at fostering innovation within Canada's life sciences sector by transforming scientific research into successful, investable businesses. The program is uniquely designed to identify and support pre-clinical technologies with substantial market potential, focusing on biopharmaceuticals, medical devices, and digital health solutions. By partnering with academic researchers and emerging companies, adMare has successfully co-created over 36 companies, providing a robust framework of support that enhances project scalability and commercial viability.
adMare's diverse team of dedicated R&D scientists, commercialization experts, and strategic partners work collaboratively with grant recipients to advance early-stage technologies towards becoming investment-ready ventures. The organization offers comprehensive support that encompasses state-of-the-art infrastructure through its well-equipped innovation centers in Montreal and Vancouver, as well as extensive networking opportunities with industry leaders and investors. These facilities are crucial for bolstering the research capabilities of candidates, accelerating development timelines, and achieving crucial drug development milestones.
A pivotal aspect of this grant is the flexible shared risk/reward model that adMare implements with its partner companies. This model ensures that all parties involved benefit from mutual growth and success, encouraging innovation and allowing for adaptive approaches to project management. Moreover, adMare's strategic emphasis on assembling experienced founding teams for new ventures is crucial in attracting private investment and scaling operations effectively.
The grant is also designed to address unmet medical needs, ensuring that selected projects have a profound impact on the healthcare landscape. adMare's ability to identify differentiated technologies with a competitive advantage allows for the creation of novel therapeutic products that can address specific gaps in the market. This, coupled with the development of a compelling business case, ensures that supported companies are well-positioned to make significant contributions to both the Canadian economy and healthcare systems globally.
By fostering a culture of innovation and collaboration, adMare's grant enables the translation of academic discoveries into impactful commercial applications. The initiative not only provides seed capital but also nurtures talent and cultivates an ecosystem ripe for life sciences advancements. Companies supported by adMare collectively hold a combined value of $5.7 billion and have created thousands of jobs, showcasing the significant economic and social impact of the program.
In conclusion, adMare's grant is an invaluable resource for Canadian life sciences projects aiming to transition from research to market. Through comprehensive support and strategic investment, adMare empowers innovators to not only advance their technologies but also contribute to a more resilient and dynamic life sciences industry in Canada. The program's commitment to quality, innovation, and collaboration solidifies its role as a key driver of progress within the sector.
